But researchers have recently made inroads into why some of those setbacks occurred in the first place. These insights have led to the development of promising new drugs that are more targeted for key appetite-control receptors in the brain and elsewhere in the body, according to the article. As a result, these drugs pose a lower likelihood of side effects while promoting weight loss. However, the reasons behind some obesity drugs' psychiatric side effects are not as clear cut, and researchers are still eager to learn more about how the brain controls food intake and how it communicates with the gut. "Obesity is so complex and so multi-factorial that it's hard to find a silver bullet," says one scientist involved in obesity drug development. "I think we're just scratching the surface."
ARTICLE #5 EMBARGOED FOR 9 A.M., EASTERN TIME, April 13, 2009
"Weighing options: Obesity researchers assess what it will take to move forward in the wake of drug-trial setbacks"
This story will be available on April 13 at
http://pubs.acs.org/cen/coverstory/87/8715cover.html
FOR ADVANCE INFORMATION, CONTACT:
Michael Bernstein
ACS News Service
Phone: 202-872-6042
Fax: 202-872-4370
Email: m_bernstein@acs.org
Journalists' Resources
Press releases, briefings, and more from ACS' Ma
'/>"/>
| Contact: Michael Woods m_woods@acs.org 202-872-6293 American Chemical Society Source:Eurekalert |